Novartis

Views & Analysis

R&D Roundup: Pharma gets in on the biotech boom

Some good news for the UK industry in turbulent times is always welcome, and several announcement this month showed us why the biotech sector in the country is looking extremely promising g

News

Novartis completes spin-out of Alcon eye unit

Novartis’ long-awaited separation from its eye care division Alcon completed on schedule today, allowing it to focus its energies on medicinal products.

News

US drug cost body calls for SMA drug price cuts

A US drug cost-effectiveness group has said that Biogen should cut the price of its already-approved spinal muscular atrophy (SMA) drug, while the $4-$5 million Novartis is suggesting for a

News

Fusion raises $105m for radiopharmaceutical trials

Radiopharmaceuticals are already well established in imaging technology for a range of diseases – but their use to deliver a lethal dose of radiation to cancer cells is also gaining increas

News

Novartis buys NASH biotech IFM Tre in potential $1.575 bn de...

Novartis is to buy US biotech IFM Tre in a deal worth up to $1.575 billion, adding a potential drug for the fatty liver disease known as NASH to its pipeline.

News